AGG Talks: Government Insight for Life Sciences Leaders Podcast Series · Arnall Golden Gregory LLP

Tell Me Lies, Tell Me Sweet Little Lies: FDA Is Not My Only Potential Headache When It Comes to Product Promotion

·29 min·2 clips

The FTC and states sued over nearly 30,000 deceptive Google Pixel endorsements tied to iHeartMedia.

A Truman Show-style good morning sets up the legal conversation. Alan Mintz starts with the show's familiar greeting, then moves into food and drug work: over-the-counter drugs, cosmetics, food-type products, and products that sit between consumer and FDA-regulated categories. Anuj Desai joins as head of trademarks, which pulls brands, advertising compliance, and dispute resolution into the same conversation as FDA-regulated promotion. The headache is bigger than FDA. The issue is what a company should do when it follows cautious promotional rules while competitors seem to make stronger, riskier claims. Marketers spot the tension fast. They bring presentations, Amazon examples, and prescription drug advertisements to counsel and ask why similar wording is still off limits. The answer is plain enough. False or misleading advertising may not get caught right away, but copying it is still a bad compliance move. Competitor conduct can hurt sales, reputation, the public, and fair competition around regulated products. The options are legal and procedural. A company can use NAD for national or regional advertising challenges when speed and cost matter. It can contact the competitor directly or send a cease-and-desist letter. Litigation remains on the table under the Lanham Act and applicable state law, including deceptive trade practice laws. If timing is urgent, a preliminary injunction may be available. The useful discipline is separating irritation at a competitor from the standard that governs your own claims.

As heard by us

A practical map of how product-promotion disputes can move beyond FDA alone.

The discussion widens product-promotion risk beyond the FDA and shows how a false or misleading claim can become a competitor, trademark, and litigation problem.

Read the full review in PlayNext →

Why you'd press play

Need the playbook when a competitor's promotion goes too far?

Read the full recommendation in PlayNext →

Listen to the show on

Apple Podcasts Spotify

Play clips from this episode More from AGG Talks: Government Insight for Life Sciences Leaders Podcast Series